Uncategorized

Compare monoclonal lab reagents for research






Suppliers for Lab Assays

HIV-2
9003 Virostat 100 ug
Description: gp36

HIV-1
8908 Virostat 100 ug
Description: gp41

HIV-1
8909 Virostat 100 ug
Description: p24

HIV-2
8911 Virostat 100 ug
Description: gp36

HIV-1
8933 Virostat 100 ug
Description: gp41

HIV-1
8941 Virostat 100 ug
Description: nef

HIV-2
8949 Virostat 100 ug
Description: gp36

Monoclonal GR monoclonal antibody
AMM00029G Leading Biology 0.05mg 633.6 EUR

Monoclonal TBP monoclonal antibody
APR13720G Leading Biology 0.1ml 633.6 EUR

Monoclonal EZH2 monoclonal antibody
AMM00030G Leading Biology 0.05mg 633.6 EUR

Monoclonal Rsf1 monoclonal antibody
AMM07673G Leading Biology 0.05mg 633.6 EUR

Monoclonal Rsf1 monoclonal antibody
AMM07674G Leading Biology 0.1ml 633.6 EUR

Monoclonal HDAC2 monoclonal antibody
AMM00031G Leading Biology 0.05mg 633.6 EUR

Monoclonal SirT1 monoclonal antibody
APR09951G Leading Biology 0.05mg 580.8 EUR

Monoclonal SirT1 monoclonal antibody
APR09952G Leading Biology 0.1ml 580.8 EUR

Our used TESTs in Pubmed.

Monoclonal FGG Antibody (monoclonal) (M01), Clone: 1F2
AMM03544G Leading Biology 0.1mg 580.8 EUR

Monoclonal GRN Antibody (monoclonal) (M01), Clone: 1F5
AMM03593G Leading Biology 0.1mg 580.8 EUR

Monoclonal GSC Antibody (monoclonal) (M01), Clone: 4H7
AMM03594G Leading Biology 0.1mg 580.8 EUR

Monoclonal HBB Antibody (monoclonal) (M01), Clone: 2H3
AMM03602G Leading Biology 0.1mg 580.8 EUR

Monoclonal HN1 Antibody (monoclonal) (M01), Clone: 2C8
AMM03628G Leading Biology 0.1mg 580.8 EUR

Uncategorized

Compare Pcr lab reagents for research




Suppliers for Lab ELISAs

N719 Dye, 95%
30786-1 Sisco Laboratories 250 Mg
Description: Part C

N719 Dye, 95%
30786-2 Sisco Laboratories 1 Gms
Description: Part C

D-149 Dye
D100020 Toronto Research Chemicals 50mg
Description: 786643-20-7

MEDIA DYE, RED
F323 PhytoTechnology Laboratories 10G

6×Loading Dye
TRI-A36S1 TRI Biotech 5×1mL

Loading Dye (6X)
LD001 Geneaid Biotech each

Loading Dye (6X)
LD010 Geneaid Biotech each

REC-1
ABC-TC0956 AcceGen 1 vial Ask for price

pGADT7-Rec
PVTY00072 Nova Lifetech 2ug 280 EUR

pGADT7-Rec
PVT4025 Nova Lifetech 2ug 216 EUR

REC-2615 (HCl)
530142 MedKoo Biosciences 10.0mg 295 EUR

Rec FLA-ST
tlrl-flic-10 InvivoGen FR 10 µg 295.05 EUR

Rec FLA-ST
tlrl-flic-50 InvivoGen FR 50 µg 731.85 EUR

rec EGF (human)
4030572.01 Bachem 0.1 mg 102.27 EUR

rec EGF (human)
4030572.05 Bachem 0.5 mg 271.85 EUR

Our used monoclonals in Pubmed.

Monoclonal HD Antibody (monoclonal) (M02), Clone: 4G6
APR12332G Leading Biology 0.1mg 580.8 EUR

Monoclonal HD Antibody (monoclonal) (M11), Clone: 3F1
APR12333G Leading Biology 0.1mg 580.8 EUR

Monoclonal NPY Antibody (monoclonal) (M01), Clone: 3B5
APR07142G Leading Biology 0.1mg 580.8 EUR

Monoclonal DAO Antibody (monoclonal) (M01), Clone: 2F5
APR07497G Leading Biology 0.1mg 580.8 EUR

Monoclonal DLD Antibody (monoclonal) (M02), Clone: 3C1
APR07594G Leading Biology 0.1mg 580.8 EUR

Uncategorized

Compare rec. lab reagents for research




Suppliers for Lab polyclonals

Dye 937
T18985-1g TargetMol Chemicals 1g
Description: Dye 937

Dye 937
T18985-1mg TargetMol Chemicals 1mg
Description: Dye 937

Dye 937
T18985-50mg TargetMol Chemicals 50mg
Description: Dye 937

Dye 937
T18985-5mg TargetMol Chemicals 5mg
Description: Dye 937

Dye 993
T18986-10mg TargetMol Chemicals 10mg
Description: Dye 993

Dye 993
T18986-1g TargetMol Chemicals 1g
Description: Dye 993

Dye 993
T18986-1mg TargetMol Chemicals 1mg
Description: Dye 993

REC-1
ABC-TC0956 AcceGen 1 vial Ask for price

pGADT7-Rec
PVTY00072 Nova Lifetech 2ug 280 EUR

pGADT7-Rec
PVT4025 Nova Lifetech 2ug 216 EUR

REC-2615 (HCl)
530142 MedKoo Biosciences 10.0mg 295 EUR

Rec FLA-ST
tlrl-flic-10 InvivoGen FR 10 µg 295.05 EUR

Rec FLA-ST
tlrl-flic-50 InvivoGen FR 50 µg 731.85 EUR

rec EGF (human)
4030572.01 Bachem 0.1 mg 102.27 EUR

rec EGF (human)
4030572.05 Bachem 0.5 mg 271.85 EUR

Our used References in Pubmed.

Rec 15/2615 dihydrochloride
MBS5757696-1mg MyBiosource 1mg 250 EUR

Rec 15/2615 dihydrochloride
MBS5757696-25mg MyBiosource 25mg 1090 EUR

Rec 15/2615 dihydrochloride
MBS5757696-50mg MyBiosource 50mg 1605 EUR

Rec 15/2615 dihydrochloride
MBS5757696-5mg MyBiosource 5mg 455 EUR

TP P17, Rec. Ag
MBS313842-1mg MyBiosource 1mg 880 EUR

Uncategorized

Compare monoclonal lab reagents for research



Suppliers for Lab recombinants

Rat TPO
MBS691621-001mg MyBiosource 0.01mg

Rat TPO
MBS691621-5x001mg MyBiosource 5x0.01mg

Rat EGF
MBS691892-002mg MyBiosource 0.02mg

Rat EGF
MBS691892-01mg MyBiosource 0.1mg

Rat EGF
MBS691892-5x01mg MyBiosource 5x0.1mg

Rat SCF
MBS692096-0002mg MyBiosource 0.002mg

Rat SCF
MBS692096-001mg MyBiosource 0.01mg

Monoclonal GR monoclonal antibody
AMM00029G Leading Biology 0.05mg 633.6 EUR

Monoclonal TBP monoclonal antibody
APR13720G Leading Biology 0.1ml 633.6 EUR

Monoclonal EZH2 monoclonal antibody
AMM00030G Leading Biology 0.05mg 633.6 EUR

Monoclonal Rsf1 monoclonal antibody
AMM07673G Leading Biology 0.05mg 633.6 EUR

Monoclonal Rsf1 monoclonal antibody
AMM07674G Leading Biology 0.1ml 633.6 EUR

Monoclonal HDAC2 monoclonal antibody
AMM00031G Leading Biology 0.05mg 633.6 EUR

Monoclonal SirT1 monoclonal antibody
APR09951G Leading Biology 0.05mg 580.8 EUR

Monoclonal SirT1 monoclonal antibody
APR09952G Leading Biology 0.1ml 580.8 EUR

Our used antibodies in Pubmed.

Vitamin B7 Test
R6001 Ring Biotechnology Co 96T 200 EUR

Vitamin B9 Test
R6002 Ring Biotechnology Co 96T 200 EUR

Single Test Kit
EKIT-009 Creative BioMart 20 assays 399.2 EUR

HBcAb Test Card
HBcAb-252 Innovation Biotech 4.0 mm (strip in a card) 25cards/box 0.32 EUR

HBeAb Test Card
HBeAb-232 Innovation Biotech 4.0 mm (strip in a card) 25cards/box 0.32 EUR

Uncategorized

recombinant Lab Reagents for Research





Promoted Lab polyclonals

Accu-Tell COVID-19 IgG/IgM Rapid Test
GEN-B352-20tests Accu test 20 tests 283.2 EUR

2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
GEN-402-25tests All test 25 tests 292.8 EUR

Human TES(Testin) ELISA Kit
EH1738 FN Test 96T 681.12 EUR

T(Testosterone) ELISA Kit
EU0400 FN Test 96T 571.5 EUR

Rat T(Testosterone) ELISA Kit
ER1462 FN Test 96T 628.92 EUR

Human Testosterone ELISA Kit
EH4850 FN Test 96T 628.92 EUR

Rat Cholesterol ELISA ELISA
E01A11128 BlueGene 96T 700 EUR

Goat Cholesterol ELISA ELISA
E01A46041 BlueGene 96T 700 EUR

Mouse Cholesterol ELISA ELISA
E01A19869 BlueGene 96T 700 EUR

Human Cholesterol ELISA ELISA
E01A2368 BlueGene 96T 700 EUR

Sheep Cholesterol ELISA ELISA
E01A98335 BlueGene 96T 700 EUR

Monkey Cholesterol ELISA ELISA
E01A72187 BlueGene 96T 700 EUR

Canine Cholesterol ELISA ELISA
E01A63475 BlueGene 96T 700 EUR

Our used rec. in Pubmed.

CD11b Antibody Antibody
E19-2911-1 EnoGene 50ug/50ul 145 EUR

CD11b Antibody Antibody
E19-2911-2 EnoGene 100ug/100ul 225 EUR

ASAP1 antibody Antibody
DF8746 Affbiotech 200ul 420 EUR

ASAP1 antibody Antibody
DF8746-100ul Affinity Biosciences 100ul 280 EUR

ASAP1 antibody Antibody
DF8746-200ul Affinity Biosciences 200ul 350 EUR

HSP60 Antibody Antibody
E8M1007-4 EnoGene 100ul 225 EUR

ZNF98 Antibody Antibody
E36403 EnoGene 100μg 275 EUR

CD11b Antibody Antibody
ABD2911 Nova Lifetech 100ug 325 EUR

CD11b Antibody Antibody
MBS8513599-005mg MyBiosource 0.05mg 235 EUR

CD11b Antibody Antibody
MBS8513599-01mg MyBiosource 0.1mg 305 EUR
A novel isolator-based system promotes viability of human embryos during laboratory processing., On the fate of primordial germ cells injected into early mouse embryos.

Downregulated RRS1 inhibits invasion and metastasis of BT549 through RPL11‑c‑Myc‑SNAIL axis

Regulator of ribosome synthesis 1 (RRS1) is a key factor in ribosome biosynthesis and other cellular functions. High level of RRS1 in breast cancer cell lines is associated with increased cell proliferation, invasion and migration. RRS1 controls the assembly of the 60s subunit and maturation of 25S rRNA during ribosome biosynthesis.
In this study, lentiviral transfection of sh‑RNA was used to knock down the level of RRS1, to detect the effect of RRS1 on cell function and to explore the specific mechanism of RRS1 affecting cell invasion and metastasis by COIP and dual‑luciferase reporter gene assays.
The present study found that RRS1 knockdown reduced the accumulation of ribosome protein L11 (RPL11) in the nucleolus, which then migrated to the nucleoplasm and bound to c‑Myc. This inhibited trans‑activation of SNAIL by c‑Myc and eventually decreased the invasion and metastasis capacity of the human breast cancer cell line BT549.
Taken together, RRS1 regulates invasion and metastasis of human breast cancer cells through the RPL11‑c‑Myc‑SNAIL axis. The findings are of great significance for exploring the mechanism of breast cancer invasion and metastasis and the corresponding regulatory factors.

Jumonji-C domain-containing protein 5 suppresses proliferation and aerobic glycolysis in pancreatic cancer cells in a c–Myc-dependent manner

Despite the importance of metabolic reprogramming in cancer cells, the molecular mechanism regulating the tumor metabolic shift is still poorly understood. Deregulation of Jumonji-C domain-containing protein 5 (JMJD5) has been associated with multiple facets of biological processes in cancer cells.
However, the role of JMJD5 in pancreatic cancer cells has seldom been discussed and requires further investigation. In the present study, by silencing or overexpressing JMJD5 in pancreatic cancer cells, we examined the impact of JMJD5 on cell proliferation and glucose metabolism. Using a dual luciferase assay, we assessed the effect of JMJD5 on the transcriptional activity of the c-Myc target gene.
Analyzing The Cancer Genome Atlas and the Gene Expression Omnibus datasets revealed that low JMJD5 expression was associated with poor prognosis in patients with pancreatic cancer.
JMJD5 loss promoted pancreatic cancer cell proliferation and induced a cellular metabolic shift from oxidative phosphorylation to glycolysis. In addition, in vivo experiments confirmed that ectopic JMJD5 expression inhibited cancer cell growth and the expression of glycolytic enzymes, such as lactate dehydrogenase and phosphoglycerate kinase 1.
Moreover, JMJD5 negatively regulated c-Myc expression, the main regulator of cancer metabolism, leading to decreased c-Myc-targeted gene expression. Overall, the present study indicated that decreased JMJD5 expression promoted cell proliferation and glycolytic metabolism in pancreatic cancer cells in a c-Myc-dependent manner.

Imaging-Based Screening of Deubiquitinating Proteases Identifies Otubain-1 as a Stabilizer of c–MYC

The ubiquitin-proteasome pathway precisely controls the turnover of transcription factors in the nucleus, playing an important role in maintaining appropriate quantities of these regulatory proteins. The transcription factor c-MYC is essential for normal development and is a critical cancer driver. Despite being highly expressed in several tissues and malignancies, the c-MYC protein is also continuously targeted by the ubiquitin-proteasome pathway, which can either facilitate or inhibit c-MYC degradation. Deubiquitinating proteases can remove ubiquitin chains from target proteins and rescue them from proteasomal digestion.
This study sought to determine novel elements of the ubiquitin-proteasome pathway that regulate c-MYC levels. We performed an overexpression screen with 41 human proteases to identify which deubiquitinases stabilize c-MYC. We discovered that the highly expressed Otubain-1 (OTUB1) protease increases c-MYC protein levels.
Confirming its role in enhancing c-MYC activity, we found that elevated OTUB1 correlates with inferior clinical outcomes in the c-MYC-dependent cancer multiple myeloma, and overexpression of OTUB1 accelerates the growth of myeloma cells. In summary, our study identifies OTUB1 as a novel amplifier of the proto-oncogene c-MYC.

Rational design of small-molecules to recognize G-quadruplexes of c–MYC promoter and telomere and the evaluation of their in vivo antitumor activity against breast cancer

DNA G4-structures from human c-MYC promoter and telomere are considered as important drug targets; however, the developing of small-molecule-based fluorescent binding ligands that are highly selective in targeting these G4-structures over other types of nucleic acids is challenging.
We herein report a new approach of designing small molecules based on a non-selective thiazole orange scaffold to provide two-directional and multi-site interactions with flanking residues and loops of the G4-motif for better selectivity.
The ligands are designed to establish multi-site interactions in the G4-binding pocket. This structural feature may render the molecules higher selectivity toward c-MYC G4s than other structures.
The ligand-G4 interaction studied with 1H NMR may suggest a stacking interaction with the terminal G-tetrad. Moreover, the intracellular co-localization study with BG4 and cellular competition experiments with BRACO-19 may suggest that the binding targets of the ligands in cells are most probably G4-structures.
Furthermore, the ligands that either preferentially bind to c-MYC promoter or telomeric G4s are able to downregulate markedly the c-MYC and hTERT gene expression in MCF-7 cells, and induce senescence and DNA damage to cancer cells. The in vivo antitumor activity of the ligands in MCF-7 tumor-bearing mice is also demonstrated.

c–Myc Targets HDAC3 to Suppress NKG2DL Expression and Innate Immune Response in N-Type SCLC through Histone Deacetylation

SCLC is an aggressive malignancy with a very poor prognosis and limited effective therapeutic options. Despite the high tumor mutational burden, responses to immunotherapy are rare in SCLC patients, which may be due to the lack of immune surveillance.
Here, we aimed to examine the role and mechanism of oncogene MYC in the regulation of NKG2DL, the most relevant NK-activating ligand in SCLC-N.
Western Blotting, Immunofluorescence, flow cytometry, quantitative real-time PCR (qRT-PCR), Co-Immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), and Cytotoxicity assay were used on H2227 cells, H446 cells, and other SCLC cell lines, and we found that c-Myc negatively regulated NKG2DL expression in SCLC-N cells. Mechanistically, c-Myc recruited HDAC3 to deacetylate H3K9ac at the promoter regions of MICA and MICB, suppressing the MICA/B expression of SCLC-N cells and the cytotoxicity of NK cells.

Myc-Tag (c-myc, myc-1 epitope tag)
MBS6507981-01mL MyBiosource 0.1mL 660 EUR

Myc-Tag (c-myc, myc-1 epitope tag)
MBS6507981-5x01mL MyBiosource 5x0.1mL 2810 EUR

Myc-Tag (c-myc, myc-1 epitope tag)
MBS6507983-01mL MyBiosource 0.1mL 660 EUR

Myc-Tag (c-myc, myc-1 epitope tag)
MBS6507983-5x01mL MyBiosource 5x0.1mL 2810 EUR

c-Myc Epitope (Myc) Antibody
abx132269-100tests Abbexa 100 tests 850 EUR

c-Myc Epitope (Myc) Antibody
20-abx132269 Abbexa
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 10 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

c-Myc Epitope (Myc) Antibody
abx130438-100l Abbexa 100 µl 850 EUR

c-Myc Epitope (Myc) Antibody
20-abx130438 Abbexa
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 20 ug
  • 50 ug
  • 100 ug
  • 200 ug
  • 1 mg

c-Myc Epitope (Myc) Antibody
abx130438-1ml Abbexa 1 ml Ask for price

c-Myc Epitope (Myc) Antibody
abx130438-200l Abbexa 200 µl Ask for price

pMXs- c- Myc
PVT10447 Lifescience Market 2 ug 361.2 EUR

pCMV- Myc- C
PVT10696 Lifescience Market 2 ug 361.2 EUR

C- Myc Plasmid
PVT7185 Lifescience Market 2 ug 319.2 EUR

c Myc antibody
10R-8403 Fitzgerald 100 ul 471.6 EUR

c Myc antibody
MBS833287-INQUIRE MyBiosource INQUIRE Ask for price

Myc-Tag (c-myc, myc-1 epitope tag) (AP)
MBS6124726-01mL MyBiosource 0.1(mL 950 EUR

Myc-Tag (c-myc, myc-1 epitope tag) (AP)
MBS6124726-5x01mL MyBiosource 5x0.1mL 4115 EUR
Treatment with selective HDAC3 inhibitor up-regulated the expression of NKG2DL on SCLC-N cells and increased the cytotoxicity of NK cells. Furthermore, analysis of the CCLE and Kaplan-Meier plotter data performed the negative correlation between MYC and NKG2DL in SCLC-N cells and the correlation with the prognosis of lung cancer patients.
Collectively, the results provided the new insight into the role and mechanism of c-Myc/HDAC3 axis in NKG2DL expression and innate immune escape of SCLC-N, suggesting the potential target for SCLC-N immunotherapy.